The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Feasibility of outpatient practice for CAR-T therapy in patients with lymphoma and multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, highlights the rationale and results of a retrospective study investigating whether hospital-based outpatient management is safe and feasible for patients receiving anti-BCMA CAR-T therapy for multiple myeloma, axicabtagene ciloleucel (axi-cel) for follicular lymphoma (FL), and brexucabtagene maraleucel (brexu-cel) for mantle cell lymphoma (MCL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Research Funding; Gamida Cell: Consultancy; Celgene: Consultancy, Research Funding; Takeda: Research Funding; Merck: Research Funding; Vineti: Consultancy; Bluebird Bio: Consultancy, Research Funding; Sorrento: Consultancy; Legend: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Juno: Consultancy; Novartis: Consultancy.
